Buch, Englisch, 392 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 781 g
Compendium for Prevention and Management
Buch, Englisch, 392 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 781 g
ISBN: 978-3-211-88889-6
Verlag: Springer Vienna
The extravasation of cytotoxic agents can result in severe local tissue damage and medical emergencies during tumour therapy. This revised compendium is intended to help clinicians assess any situation speedily and with certainty. The general section of the book includes topics such as predisposition, prevention, type of harm, general measures in handling extravasated drugs, specific antidotes, and documentation. In the 2nd edition, the scientific information contained in the general section and relating to the actual substances has been updated. The substance specific part of the book includes detailed instructions on handling more than 50 cytotoxic drugs, to initiate targeted measures. Templates for an extravasation set, overview tables, documentation sheets, and patient information, as we as a CD-ROM are included to support clinical practice. The book is the outcome of a consensus of an interdisciplinary working group that has collected and systematically reviewed all published literature on the topic.
Zielgruppe
Professional/practitioner
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pflege Krankenpflege
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hämatologie, Transfusionsmedizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
Weitere Infos & Material
Problem outline.- Problem outline.- General part.- and definitions.- Predisposition and prevention.- Clinical practice.- Measures.- Aftercare.- Documentation.- Forming clinical working groups.- Quality control and quality assurance.- Open questions and outlook.- Substance-specific part.- Remarks on the substance-specific part.- Amsacrine.- L-Asparaginase.- Bendamustine.- Bleomycin.- Bortezomib.- Busulfan.- Carboplatin.- Carmustine.- Cisplatin.- Cladribine.- Cyclophosphamide.- Cytarabine.- Dacarbazine.- Dactinomycin.- Daunorubicin.- Daunorubicin liposomal.- Docetaxel.- Doxorubicin.- Doxorubicin liposomal, Doxorubicin pegylated liposomal.- Epirubicin.- Estramustine.- Etoposide.- Etoposide phosphate.- Fludarabine.- 5-Fluorouracil.- Fotemustine.- Gemcitabine.- Idarubicin.- Ifosfamide.- Irinotecan.- Melphalan.- Methotrexate.- Mitomycin C.- Mitoxantrone.- Nimustine.- Oxaliplatin.- Paclitaxel.- Pegaspargase.- Pemetrexed.- Pentostatin.- Raltitrexed.- Streptozocin.- Teniposide.- Thiotepa.- Topotecan.- Treosulfan.- Trimetrexate.- Vinblastine.- Vincristine.- Vindesine.- Vinorelbine.
